Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2007-006025-27-IT
EUCTR2007-006025-27-IT
Active, not recruiting
Not Applicable

A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast cancer

ISTITUTO EUROPEO DI ONCOLOGIA0 sitesFebruary 20, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsadvanced or metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
DrugsENDOXAN BAXTER*50CPR RIV 50MGXELODA*120CPR RIV 500MGAVASTIN*INFUS 1FL 100MG 4MLTARCEVA*30CPR RIV 150MGHERCEPTIN*EV 1FL 150MG

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
advanced or metastatic breast cancer
Sponsor
ISTITUTO EUROPEO DI ONCOLOGIA
Status
Active, not recruiting
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 20, 2008
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Pre\- or post\-menopausal women with histologically proven, locally advanced
  • •(inoperable) or metastatic breast carcinoma.
  • •Immunohistochemical receptor status at the last biopsy available:
  • •ER and PgR absent (0% of the cells) or
  • •ER or PgR Absent or
  • •ER and PgR ≤ 50% of the cells
  • •Measurable disease
  • •Age \>18 years
  • •Life expectancy of greater than 6 months.
  • •Are the trial subjects under 18? no

Exclusion Criteria

  • •Previous treatment with bevacizumab, EGFR inhibitors or metronomic cyclophosphamide \+ capecitabine.
  • •Immunohistochemical receptor status at the last biopsy available:
  • •ER and PgR≥50%
  • •Presence of cerebral or leptomeningeal involvement.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancerMetastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2010-024266-21-ITISTITUTO EUROPEO DI ONCOLOGIA100
Active, not recruiting
Not Applicable
A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer - NDPre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer.
EUCTR2009-017083-16-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
Active, not recruiting
Phase 1
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
Active, not recruiting
Phase 1
Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumor
EUCTR2021-002540-67-FRCentre Oscar Lambret28
Completed
Phase 3
ANZ 0001 Capecitabine vs CMF in Advanced Breast Cancer
ACTRN12606000379516Breast Cancer Trials (formerly Australian New Zealand Breast Cancer Trials Group)325